The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Kidney transplantation is the best possible treatment for many patients with end-stage renal
failure, but progressive dysfunction and eventual allograft loss with return to dialysis is …

Although cold ischemia time has been widely studied in renal transplantation area, there is
no consensus on its precise relationship with the transplantation outcomes. To study this, we …

Advances in maintenance immunosuppression over the past three decades have improved
solid organ transplantation outcomes dramatically. Uninterrupted access to …

Using meta-analysis of eight independent transplant datasets (236 graft biopsy samples)
from four organs, we identified a common rejection module (CRM) consisting of 11 genes …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

In kidney transplant recipients, cancer is one of the leading causes of death with a
functioning graft beyond the first year of kidney transplantation, and malignancies account …

Outcomes of kidney transplantation, in terms of graft and patient survival, have improved
over the past few decades, partly as a result of the introduction of new immunosuppressive …

Background Modern immunosuppressive regimens after kidney transplantation usually use
a combination of two or three agents of different classes to prevent rejection and maintain …

Background There is lack of recent multicenter epidemiological data on invasive
aspergillosis (IA) among solid organ transplant recipient (SOT r) in the mold‐acting …